Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256667 | 0.93 | DUT (0.42) | DUT | |
| SCHEMBL8063404 | 0.88 | DUT (0.43) | DUT | |
| SCHEMBL27241092 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL14245094 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL9007756 | 0.85 | DUT (0.42) | DUT | |
| SCHEMBL2255607 | 0.83 | DUT (0.38) | DUT | |
| SCHEMBL28538333 | 0.83 | DUT (0.43) | DUT | |
| SCHEMBL345800 | 0.82 | DUT (0.38) | DUT | |
| SCHEMBL3272074 | 0.80 | DUT (0.37) | DUT | |
| SCHEMBL5856290 | 0.80 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073885-B2 | Vitamin D3 lactone derivatives | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-1589009-B1 | VITAMIN D3 LACTONE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2363390-A1 | DERIVED LACTAM FROM D3 VITAMIN | Teijin Pharma Limited (JP) | 2011-09-07 | — | — | EP | disclosed |
| US-20110207944-A1 | VITAMIN D3 LACTAM DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20060148768-A1 | Vitamin d3 lactone derivatives | TEIJIN LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1589009-A1 | VITAMIN D3 LACTONE DERIVATIVE | Teijin Pharma Limited (JP) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148768-A1 | Vitamin d3 lactone derivatives | VDR, CYP24A1, CYP2R1 | DUT 2761/4885 |
| US-20110207944-A1 | VITAMIN D3 LACTAM DERIVATIVE | VDR, CYP24A1, CYP2R1 | DUT 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.